Compare JetBlue Airways Corporation (JBLU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Natera Inc. Common Stock — how do they compare? JetBlue Airways Corporation trades at $3.03 (market cap $1.26B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 45.3× JetBlue Airways Corporation's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Natera Inc. Common Stock for 0 Days on average.
| JBLU | NTRA | |
|---|---|---|
Market Cap | $1.26B | $57.03B |
Volume | 40,642,525 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $6.46 | $425.64 |
52-Week Low | $3.01 | $179.42 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.63B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.01, down 16.85% in the last 24 hours, reflecting significant bearish pressure. The stock exhibits weak fundamentals with a negative net income margin of -9.32% and consecutive quarterly losses, though it beat EPS expectations in Q2 2026. Technical indicators are predominantly bearish, with the stock trading near key support levels. Recent news highlights expansion efforts like new routes to Colombia and the launch of BlueFirst premium seating, aiming to boost revenue amid industry challenges.
The outlook remains challenging due to persistent losses, high debt levels, and elevated fuel costs. While analyst consensus suggests a hold rating with a $5.89 price target implying potential upside, risks from competitive pressures and macroeconomic factors dominate. Investment appeal is limited to speculative positions betting on a operational turnaround despite current headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
